Estradiol (MINIVELLE) – USA

Estradiol (MINIVELLE) – USA

IPR decision (Sep 10, 2018):

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Final Written Decision
IPR2018-01119
05/18/2018
Mylan
9,833,419
Terminated-Settled
US  9,833,419 (Noven Pharmaceuticals, Inc.; Exp: 07/10/2028):
1. A monolithic transdermal drug delivery system for estradiol, consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer defining an active surface area and, optionally, (iii) a release liner, wherein the single adhesive polymer matrix layer comprises an adhesive polymer matrix comprising estradiol as the only drug, wherein the adhesive polymer matrix layer has a coat weight of greater than 10 mg/cm.sup.2 and includes greater than 0.156 mg/cm.sup.2 estradiol, and the system achieves an estradiol flux of from 0.0125 to about 0.05 mg/cm.sup.2/day, based on the active surface area.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved